Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 597 results for "celgene corporation headquarters"

Celgene, Juno Therapeutics ink collaboration to develop and co...

Celgene Corporation, an integrated global biopharmaceutical company, and Juno Therapeutics, Inc., a fully integrated biopharmaceutical company, have entered into a global collaboration for the development and commercialization of immunotherapies. PharmaBiz, 4 days ago
[x]  
TeleTrader.com

Celgene Announces Additional and#36;4 Billion Share Repurchase Authorization

World News: 12:30 GMT Wednesday 17th June 2015 . [ Celgene Corporation via Businesswire via SPi World News ] This story Celgene Corporation (NASDAQ:CELG) today announced that during its June meeting the Company's Board of Directors ...
 SPi World News2 weeks ago Celgene Announces Additional $4 Billion Share Repurchase Authorization  MoneyShow.com2 weeks ago CELGENE : Announces Additional $4 Billion Share Repurchase Authorization  4 Traders2 weeks ago Celgene Release: Results From Analyses Of Revlimid MCL-002 (SPRINT) Study Presented At European Hematology Association  BioSpace2 weeks ago
[x]  

FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Beta-Thalassemia

SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma Inc. (NASDAQ:XLRN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designations to ...
 CNBC1 month ago Celgene (CELG) Release: FDA Fast Track Designation Granted To Luspatercept For The Treatment Of Patients With Beta-Thalassemia 5/18/2015  ClinicSpace1 month ago ACCELERON PHARMA : FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Beta-Thalassemia  4 Traders1 month ago Celgene Release: FDA Fast Track Designation Granted To Luspatercept For The Treatment Of Patients With Beta-Thalassemia  BioSpace1 month ago
[x]  

Corporate Reputation of Pharma in 2014 - A Perspective of Cancer Patient Groups

/PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/z44b5x/corporate ) has announced the addition of the "Corporate Reputation of Pharma in 2014 - a Perspective of Cancer Patient Groups - 2nd Edition" report to their ...
 Crawford Financial Planning2 weeks ago Research and Markets: Corporate Reputation of Pharma in 2014 - A Perspective of Cancer Patient Groups  TMC Net3 weeks ago RESEARCH AND MARKETS : Corporate Reputation of Pharma in 2014 - A Perspective of Cancer Patient Groups  4 Traders3 weeks ago
[x]  

11th Annual Public Relations & Communications Summit to be Held July 20-21, 2015 at Sanofi US Headquarters

PR Newswire NEW YORK, June 9, 2015 NEW YORK More than 150 participants will discuss industry topics such as multichannel communications, change management, technological innovations, employee engagement, pricing and policy changes, the evolving ...
 Reuters3 weeks ago
[x]  

City confirms plans for former Merck site to be Celgene campus

3-Jul-2015 Manufacturing | North America The city of Summit (New Jersey, USA) has confirmed that the former Merck campus at 556 Morris Avenue is now contracted to Celgene. Celgene is an exceptional company and a pre-eminent leader in the ...
 Manufacturing Chemist2 days ago

CELGENE : FORMA Therapeutics Achieves Clinical Candidate Licensing Milestone for an Epigenetic Compound in Strategic Alliance with Celgene Corporation

By a News Reporter-Staff News Editor at Biotech Week -- FORMA Therapeutics (FORMA) announced that they have successfully met a preclinical development candidate milestone in their strategic collaboration agreement with Celgene Corporation , ...
 4 Traders1 week ago FORMA Therapeutics Achieves Clinical Candidate Licensing Milestone for an Epigenetic Compound in Strategic Alliance with Celgene Corporation  EON: Enhanced Online News2 weeks ago FORMA Therapeutics, Inc. Achieves Clinical Candidate Licensing Milestone For An Epigenetic Compound In Strategic Alliance With Celgene  BioSpace2 weeks ago FORMA Therapeutics : Achieves Clinical Candidate Licensing Milestone for an Epigenetic Compound in Strategic Alliance with Celgene Corporation  4 Traders2 weeks ago
[x]  

CELGENE : UT Arlington alumna's gift will provide international business students opportunities to engage the world

Global reach Jacqualyn Fouse knows the value of an international experience for a business student's portfolio. It was a high school trip to France that whetted Fouse's appetite for a career in international business and set her on a path for a ...
 4 Traders1 month ago UTA alumna's gift will provide business students opportunities to engage the world  EurekAlert!1 month ago

CELGENE : CRISPR Therapeutics Gets Additional $64 Million in Funding

CRISPR Therapeutics, a biopharmaceutical company focused on translating CRISPR-Cas9, a breakthrough gene-editing technology into transformative medicines, reported that it recently closed a Series A and Series B financing totaling USD 89 million , ...
 4 Traders2 months ago
TheStreet.com

Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point

Reddit Email Print Reprint BOSTON ( TheStreet ) -- This week's Biotech Stock Mailbag is abbreviated and delivered a day early due to the Fourth of July. Happy hot dogs and fireworks, everyone! @adamfeuerstein Let's get a halftime ...
 TheStreet.com3 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - celgene corporation headquarters
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less